About Us

Welcome to The Biomarkers Consortium! The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers. The consortium was formally launched in late 2006 to identify and qualify new, quantitative biological markers (“biomarkers”), for use by biomedical researchers, regulators and health care providers. Effective identification and deployment of biomarkers is essential to achieving a new era of predictive, preventive and personalized medicine. Biomarkers promise to accelerate basic and translational research, speed the development of safe and effective medicines and treatments for a wide range of diseases, and help guide clinical practice.

The Biomarkers Consortium is a major public-private biomedical research partnership managed by the Foundation for NIH with broad participation from stakeholders across the health enterprise, including government, industry, academia and patient advocacy and other non-profit private sector organizations. In addition to the Foundation for NIH, founding members include the National Institutes of Health, Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America. Other partners in the consortium include the Centers for Medicare & Medicaid Services and the Biotechnology Industry Organization.

Some of the most useful biomarkers took years of development to achieve the elevated status they now hold in medicine. One of the most difficult tasks facing biomarker assessment and evaluation is harmonizing the approaches of various stakeholders--government, industry, non-profits and foundations, providers, and academic institutions. Our partners recognize the critical need for a coordinated cross-sector partnership effort.

For partnership or additional information about The Biomarkers Consortium, please email us at biomarkers@fnih.org. For more information about the Foundation for the National Institutes of Health go to www.fnih.org.

 

 

  • About Biomarkers

    Biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention. More

  • Join Us

    Become a Member
    Learn how you can join and support The Biomarkers Consortium.

    The Biomarkers Consortium embraces government, industry, patient advocacy groups, and non-profit organizations, each of which has a stake in the development of biomarker technology.

  • Latest News

    THE BIOMARKERS CONSORTIUM LAUNCHES I-SPY 2 BREAST CANCER CLINICAL TRIAL:  Click here to read the press release.

    March 17, 2010 -- Announcing the launch of the Biomarkers Consortium I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and moLecular analysis): An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy), which is taking place today from 9-10:30 a.m. ET at the National Press Club, Washington, DC.  Click here for more information.

    View the Web Cast

     

    Six awardees conducting data analysis to Develop Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults: Click here to read

    The Metabolic Disorders Steering Committee releases strategy for Mathematical Modeling in Atherosclerosis:  Details

    PRESS RELEASE:  The Biomarkers Consortium Completes First Project to Show That Adiponectin is a Predictive Biomarker for Type 2 Diabetes:  Click here to read

    RFP for Data Analysis to Develop Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults.  Due Date: September 8, 2009.  Click here to read.

     

    Available Now: The Biomarkers Consortium Report, Volume 1, Issue 1, May 2009. Click Here to Read

    The Metabolic Disorders Steering Committee Prioritized Areas of Unmet Need: As advertised in Volume 58, No. 4, April 2009 issue of Diabetes.  Click Here to read.

    Presentations Available from the Beta Cell Function Symposium. Click here for agenda.